Phase 3
Completed N=40
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Source: ClinicalTrials.gov NCT00759291 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcomePrimary: Flow Mediated Vasodilation — 9.5; 10.8; 10.5; 10.9 percentage of vasodilation
◆ Published Evidence
Emerging
12citations · ~2 / year
Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
Summary
This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.
Linked Publications (2)
-
Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
-
The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Flow Mediated Vasodilation |
9.5; 10.8; 10.5; 10.9 | — |
Eligibility Criteria
Inclusion Criteria
- Adults with metabolic syndrome, defined as the presence of 3 of 5 components of the syndrome as defined by the National Cholesterol Education Program including:
- abdominal obesity
- elevated fasting blood sugar (110 mg/dL 150 mg/dL)
- hypertension (BP > 140/90 mm HG)
- Normal cardiovascular examination
Exclusion Criteria
- Diabetes mellitus
- Untreated hypercholesterolemia (LDL > 75th percentile for age)
- Cigarette smoking within 1 year
- Renal insufficiency (creatinine > 1.4 mg/dl)
- Blood dyscrasia
- Hepatic dysfunction (ALT > 2x normal)
- Evident coronary/peripheral atherosclerosis
Data sourced from ClinicalTrials.gov (NCT00759291) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.